Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:9792222rdf:typepubmed:Citationlld:pubmed
pubmed-article:9792222lifeskim:mentionsumls-concept:C0031809lld:lifeskim
pubmed-article:9792222lifeskim:mentionsumls-concept:C0007452lld:lifeskim
pubmed-article:9792222lifeskim:mentionsumls-concept:C0006104lld:lifeskim
pubmed-article:9792222lifeskim:mentionsumls-concept:C0033572lld:lifeskim
pubmed-article:9792222lifeskim:mentionsumls-concept:C1882687lld:lifeskim
pubmed-article:9792222lifeskim:mentionsumls-concept:C0257343lld:lifeskim
pubmed-article:9792222lifeskim:mentionsumls-concept:C1167622lld:lifeskim
pubmed-article:9792222lifeskim:mentionsumls-concept:C1510827lld:lifeskim
pubmed-article:9792222lifeskim:mentionsumls-concept:C0449560lld:lifeskim
pubmed-article:9792222pubmed:issue4lld:pubmed
pubmed-article:9792222pubmed:dateCreated1999-1-20lld:pubmed
pubmed-article:9792222pubmed:abstractText1. The present study was designed to assess the displacement potencies of tamsulosin to 3H-prazosin bindings in two alpha1-adrenoceptor (AR) subtypes (alpha1H and alpha1L) in bovine prostate, rat heart and brain compared with those of amosulalol, labetalol, ketanserin, clonidine and propranolol. 2. The pKi values of tamsulosin to alpha1H and alpha1L subtypes in bovine prostate were 9.13 and 8.99 and these values were almost the same as those of prazosin. On the other hand, low pKi binding values of amosulalol, labetalol, ketanserin, clonidine and propranolol to these subtypes were observed. 3. Low pKi values of tamsulosin to alpha2- and beta-ARs and muscarinic and 5HT2 receptors in the rat brain were observed. 4. These results suggest that tamsulosin has high affinities to alpha1L-AR subtypes in bovine prostate and rat hearts as well as alpha1H-AR subtypes, implying an inhibitory effect of this drug on the contraction of the prostate.lld:pubmed
pubmed-article:9792222pubmed:languageenglld:pubmed
pubmed-article:9792222pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9792222pubmed:citationSubsetIMlld:pubmed
pubmed-article:9792222pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9792222pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9792222pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9792222pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9792222pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9792222pubmed:statusMEDLINElld:pubmed
pubmed-article:9792222pubmed:monthOctlld:pubmed
pubmed-article:9792222pubmed:issn0306-3623lld:pubmed
pubmed-article:9792222pubmed:authorpubmed-author:WatanabeKKlld:pubmed
pubmed-article:9792222pubmed:authorpubmed-author:NakamuraTTlld:pubmed
pubmed-article:9792222pubmed:authorpubmed-author:MaruyamaKKlld:pubmed
pubmed-article:9792222pubmed:authorpubmed-author:SugiyamaKKlld:pubmed
pubmed-article:9792222pubmed:authorpubmed-author:NagatomoTTlld:pubmed
pubmed-article:9792222pubmed:authorpubmed-author:OhnukiTTlld:pubmed
pubmed-article:9792222pubmed:authorpubmed-author:YoshiharaTTlld:pubmed
pubmed-article:9792222pubmed:authorpubmed-author:FukutomiJJlld:pubmed
pubmed-article:9792222pubmed:authorpubmed-author:HattorimKKlld:pubmed
pubmed-article:9792222pubmed:issnTypePrintlld:pubmed
pubmed-article:9792222pubmed:volume31lld:pubmed
pubmed-article:9792222pubmed:ownerNLMlld:pubmed
pubmed-article:9792222pubmed:authorsCompleteYlld:pubmed
pubmed-article:9792222pubmed:pagination597-600lld:pubmed
pubmed-article:9792222pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:9792222pubmed:meshHeadingpubmed-meshheading:9792222-...lld:pubmed
pubmed-article:9792222pubmed:meshHeadingpubmed-meshheading:9792222-...lld:pubmed
pubmed-article:9792222pubmed:meshHeadingpubmed-meshheading:9792222-...lld:pubmed
pubmed-article:9792222pubmed:meshHeadingpubmed-meshheading:9792222-...lld:pubmed
pubmed-article:9792222pubmed:meshHeadingpubmed-meshheading:9792222-...lld:pubmed
pubmed-article:9792222pubmed:meshHeadingpubmed-meshheading:9792222-...lld:pubmed
pubmed-article:9792222pubmed:meshHeadingpubmed-meshheading:9792222-...lld:pubmed
pubmed-article:9792222pubmed:meshHeadingpubmed-meshheading:9792222-...lld:pubmed
pubmed-article:9792222pubmed:meshHeadingpubmed-meshheading:9792222-...lld:pubmed
pubmed-article:9792222pubmed:meshHeadingpubmed-meshheading:9792222-...lld:pubmed
pubmed-article:9792222pubmed:meshHeadingpubmed-meshheading:9792222-...lld:pubmed
pubmed-article:9792222pubmed:meshHeadingpubmed-meshheading:9792222-...lld:pubmed
pubmed-article:9792222pubmed:meshHeadingpubmed-meshheading:9792222-...lld:pubmed
pubmed-article:9792222pubmed:year1998lld:pubmed
pubmed-article:9792222pubmed:articleTitleTamsulosin: assessment of affinity of 3H-prazosin bindings to two alpha1-adrenoceptor subtypes (alpha1H and alpha1L) in bovine prostate and rat heart and brain.lld:pubmed
pubmed-article:9792222pubmed:affiliationDepartment of Pharmacology, Niigata College of Pharmacy, Japan.lld:pubmed
pubmed-article:9792222pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:9792222pubmed:publicationTypeIn Vitrolld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9792222lld:pubmed